Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Sep 30;10(10):735-48.
doi: 10.1038/nrd3550.

Integrating Predictive Biomarkers and Classifiers Into Oncology Clinical Development Programmes

Affiliations
Review

Integrating Predictive Biomarkers and Classifiers Into Oncology Clinical Development Programmes

Robert A Beckman et al. Nat Rev Drug Discov. .

Abstract

The future of drug development in oncology lies in identifying subsets of patients who will benefit from particular therapies, using predictive biomarkers. These technologies offer hope of enhancing the value of cancer medicines and reducing the size, cost and failure rates of clinical trials. However, examples of the failure of predictive biomarkers also exist. In these cases the use of biomarkers increased the costs, complexity and duration of clinical trials, and narrowed the treated population unnecessarily. Here, we present methods to adaptively integrate predictive biomarkers into clinical programmes in a data-driven manner, wherein these biomarkers are emphasized in exact proportion to the evidence supporting their clinical predictive value. The resulting programme demands value from predictive biomarkers and is designed to optimally harvest this value for oncology drug development.

Similar articles

See all similar articles

Cited by 22 articles

See all "Cited by" articles

References

    1. Stat Med. 2006 Oct 15;25(19):3250-69; discussion 3297-301, 3302-4, 3313-4, 3326-47 - PubMed
    1. Biom J. 2006 Aug;48(4):623-34 - PubMed
    1. J Biopharm Stat. 2009;19(3):424-36 - PubMed
    1. Clin Cancer Res. 2008 Oct 1;14(19):5984-93 - PubMed
    1. J Clin Oncol. 2008 Apr 1;26(10 ):1626-34 - PubMed

Substances

LinkOut - more resources

Feedback